$SRPT News

A Look At Sarepta Therapeutics (SRPT) Valuation After Q1 Profitability Return And Pipeline Progress

Sarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush Says

Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?

Sarepta tumbles as its gene therapy sales decline further

Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained

Sarepta Stock Slumps. Why an Earnings Beat Wasn’t Enough for the S&P 500 Loser.

Sarepta Therapeutics Q1 Earnings Call Highlights

Sarepta Therapeutics, Inc. Q1 2026 Earnings Call Summary

Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript

Sarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to Say

Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates

Sarepta Therapeutics (NASDAQ:SRPT) Q1 2026 Earnings Beat Overshadowed by Revenue Dip

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

Sarepta Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation

A Look At Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Volatility

Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk

OCGN's Gene-Agnostic Strategy Could Reset Retinal Therapy

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

Sarepta Therapeutics Seen Benefiting From New Elevidys Study, Better US Uptake in Second Half of 2026

HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target